MADRID — Semaglutide (Wegovy) prevents major cardiac events including death in adults with overweight/obesity and cardiovascular disease (CVD), both with and without impaired kidney function, a […]

MADRID — Real-world data on tirzepatide (Eli Lilly and Company) from a large population database suggest a safety profile of the drug consistent with that in […]

TOPLINE:  A systematic review and meta-analysis of 17 million individuals reports that there is a bidirectional association between asthma and type 2 diabetes (T2D) and that […]

Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer’s disease than those receiving dipeptidyl […]

Obesity prevalence in the United States “remains high,” according to newly released population data from the US Centers for Disease Control and Prevention (CDC). The data, […]

MADRID — Patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) show significant reductions in the risk of developing neurodegenerative disorders including Alzheimer’s […]

MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to […]

TOPLINE: MADRID — In children with a genetic susceptibility to type 1 diabetes (T1D), a higher consumption of oats, fruits, or rye may increase the risk […]

MADRID — Novo Nordisk’s investigational once-weekly combination of insulin icodec plus semaglutide (IcoSema) could benefit people with type 2 diabetes who don’t reach target glycemic goals […]